Serenium, Inc. v. Zhou

District Court, N.D. California·Decided July 22, 2021·No. 5:20-cv-02132·Unknown

Opinion

SERENIUM, INC., Case No. 20-cv-02132-BLF

Plaintiff, ORDER GRANTING DEFENDANTS’ v. MOTION TO DISMISS THE SECOND AMENDED COMPLAINT JASON ZHOU, et al., [Re: ECF 86] Defendants.

Before the Court is Defendants’ Motion to Dismiss the Second Amended Complaint under Fed. R. Civ. P 12(b)(2), (6), and (7) or to Compel Arbitration. Mot., ECF 86; see also Opp., ECF 93; Reply, ECF 100. The Court held a hearing on this motion on May 6, 2021. For the reasons discussed at the hearing and below, the Court GRANTS the Defendants’ Motion to Dismiss for Lack of Personal Jurisdiction WITHOUT LEAVE TO AMEND. Serenium, a start-up company with its operational headquarters in Palo Alto, California and a technology development office in San Diego, California, was founded to develop technology relating to diagnosis and treatment of sleep apnea. ECF 82, Second Amended Complaint (“SAC”) ¶ 1, 8. Serenium claims that it was approached by Defendant Jason Zhou (“Zhou”), a billionaire with interests in the British Virgin Islands, Cayman Islands, Hong Kong, and China. SAC ¶¶ 13, 63. Zhou is the founder, CEO, chairman, and controlling shareholder of Defendant New Century Healthcare Holding Co. Limited (“New Century”), which operates a number of hospitals in China. SAC ¶ 13. The parties entered into a joint venture in which Serenium developed sleep apnea technology and products that New Century would distribute and sell in Japan, South Korea, China, Serenium disclosed its proprietary technology pursuant to a non-disclosure agreement (“NDA”) to New Century. SAC ¶¶ 14-16, 20, 63-85. The NDA provided that it was “governed by Illinois law.” SAC ¶ 76. In late 2017, the parties began drafting Term Sheets that delineated the basic structure of the joint venture. SAC ¶¶ 93, 94, 99. The Term Sheets expressly stated that they would be replaced by a joint venture contract, known as the “Framework Contract,” which would in turn be replaced by a detailed Shareholder Agreement. SAC ¶ 103. Beginning in January 2018, the parties exchanged twenty-one Framework Contract drafts. SAC ¶ 104. The Framework Contract drafts contemplated Serenium and Beijing Jiarun Yunzhong Health Technology Company Ltd. (“Beijing Jiarun”) as parties. SAC ¶ 105. According to Serenium, Zhou and Defendant Jia Xiaofeng (“Jia”), New Century’s Corporate Secretary and Beijing Jiarun’s CEO, falsely held out Beijing Jiarun as part of New Century. SAC ¶¶ 17, 20, 105-108. Serenium and Beijing Jiarun ultimately opted not to enter into the contract. SAC ¶¶ 111-112. Zhou later proposed that Serenium and non-party New Century (International) Co. Limited (“New Century International”), a New Century subsidiary, form a jointly owned holding company in Hong Kong aimed at “bring[ing] Serenium’s technology to China and other Asian countries.” SAC ¶¶ 113, 122. The holding company would allegedly be funded by New Century International, while Serenium would contribute the technology. SAC ¶¶ 114-115. This agreement was memorialized as the Framework Contract. See SAC ¶¶ 114-119. As part of the Framework Contract, New Century International had the option to purchase 19.9% of Serenium’s equity based on a $25 million valuation. SAC ¶ 115. Given “the protracted but fruitful negotiation of the Framework Contract, Serenium hired engineers and opened a San Diego Technology office.” SAC ¶ 120. As months passed, however, New Century International failed to form the holding company contemplated by the Framework Contract. SAC ¶ 121. In the meantime, Serenium began to attempt compliance with Chinse regulatory requirements. SAC ¶¶ 121-124. In August 2018, New Century, at Zhou’s direction, resolved not to form the holding company, and instead represented to Serenium that it needed Serenium to provide yet more information about its trade secrets so that New Century and Beijing Jiarun could use this information in providing their own in-house adult and pediatric sleep diagnostics and treatment. For this reason, New Century, Zhou, and Jia withheld from Serenium Zhou and New Century’s decision to abandon the JV.” SAC ¶ 130. Serenium continued to share its proprietary information, business plans, testing equipment, and trade secrets. SAC ¶¶ 131-135. For example, in October 2018, Serenium trained hundreds of doctors and medical professionals— represented to be employees of New Century—in Beijing on Serenium’s technology. SAC ¶ 135. By late 2018, the relationship between the parties broke down as Zhou refused to form the holding company. SAC ¶ 137. In March 2019, New Century International terminated the Framework Contract. New Century, however, refused to return Serenium’s proprietary oximeters and failed to return or destroy Serenium’s trade secrets as required by the NDA. SAC ¶¶ 140-141. According to Serenium, New Century is currently diagnosing and treating patients with Serenium’s confidential information and intellectual property. SAC ¶ 142. On March 27, 2020, Serenium sued New Century for breach of contract, see SAC ¶¶ 211- 223, and New Century, Zhou, and Jia for misappropriation of trade secrets under 18 U.S.C. §§ 1836(b) and 1837, see SAC ¶¶ 224-250 and California Civil Code §§ 3426, et seq., see SAC ¶¶ 251-254. Serenium’s claims are predicated solely on New Century’s obligations flowing from and conduct related to the NDA. SAC ¶¶ 212, 226, 242. Accordingly, the Court is precluded from considering factual allegations related to the Framework Contract, to which nonparty New Century International was a signatory. At top, the Court recognizes that Plaintiff has made extensive amendments to the pleadings. Compare SAC with First Amended Complaint (“FAC”), ECF 14. These amendments provide valuable details about the relationship between the parties and the relationship between Defendants and the State of California. See, e.g., SAC ¶¶ 164-210. Nonetheless, the new allegations do not shift the fundamental nature of Defendants’ connection to the State of California, and Plaintiff cannot escape this Court’s previous conclusion that it lacks jurisdiction A. Lack of Personal Jurisdiction, Fed. R. Civ. P. 12(b)(2) When a defendant raises a challenge to personal jurisdiction, the plaintiff bears the burden of establishing that jurisdiction over each defendant is proper. Ranza v. Nike, Inc., 793 F.3d 1059, 1068 (9th Cir. 2015). “Although the plaintiff cannot ‘simply rest on the bare allegations of its complaint,’ uncontroverted allegations in the complaint must be taken as true. Conflicts between parties over statements contained in affidavits must be resolved in the plaintiff's favor.” Schwarzenegger v. Fred Martin Motor Co., 374 F.3d 797, 800 (9th Cir. 2004) (internal citations omitted). For a court to exercise personal jurisdiction over a nonresident defendant, that defendant must have at least “minimum contacts” with the relevant forum such that the exercise of jurisdiction “does not offend traditional notions of fair play and substantial justice.” Id. at 801 (9th Cir. 2004) (quoting International Shoe Co. v. Washington, 326 U.S. 310, 316 (1945)). Where there is no applicable federal statute governing personal jurisdiction, the district court applies the law of the state in which the district court sits. See Fed. R. Civ. P. 4(k)(1)(A); Panavision Int'l, L.P. v. Toeppen,

Serenium, Inc. v. Zhou, (N.D. Cal. 2021).

Serenium, Inc. v. Zhou (Serenium, Inc. v. Zhou) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
McGee v. International Life Insurance
355 U.S. 220 (Supreme Court, 1957)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Boschetto v. Hansing
539 F.3d 1011 (Ninth Circuit, 2008)
Walden v. Fiore
134 S. Ct. 1115 (Supreme Court, 2014)
Flood v. Bank of America Corporation
780 F.3d 1 (First Circuit, 2015)
Bernard Picot v. Dean Weston
780 F.3d 1206 (Ninth Circuit, 2015)
Loredana Ranza v. Nike, Inc.
793 F.3d 1059 (Ninth Circuit, 2015)
Axiom Foods, Inc. v. Acerchem International, Inc.
874 F.3d 1064 (Ninth Circuit, 2017)
Dole Food Co. v. Watts
303 F.3d 1104 (Ninth Circuit, 2002)
Schwarzenegger v. Fred Martin Motor Co.
374 F.3d 797 (Ninth Circuit, 2004)
Roth v. Garcia Marquez
942 F.2d 617 (Ninth Circuit, 1991)